HEALWELL Provides Corporate Update on Accelerating Commercialization and Expansion of Pharmaceutical Partnerships by Leveraging Its Best-in-Class Patient Identification Capabilities

• HEALWELL's AI and data science subsidiaries have executed 5 new Master Services Agreements ("MSA") with new pharmaceutical partners in Q3-2024; bringing the total number of MSAs with life sciences partners to 27, which includes 6 of the top 10 pharmaceutical companies in the world. HEALWELL's AI and data science subsidiaries generated patient identification revenue from 23 of these pharmaceutical partners in Q3-2024.
• HEALWELL subsidiary, Khure Health, has executed an MSA for patient identification purposes with a major multi-national medical device conglomerate highlighting an expansion into a broader life sciences customer base.
• In addition, HEALWELL's Pentavere subsidiary has executed a commercial agreement with a major U.S. health system, utilizing Pentavere's DARWEN™ AI platform to identify patients with valvular heart disease.

Toronto, Ontario--(Newsfile Corp. - November 5, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to provide a corporate update highlighting the recent success of its AI and data science business unit in accelerating the commercialization of its solutions and expanding new relationships with life sciences and pharmaceutical partners. HEALWELL's AI and data science subsidiaries executed 5 Master Service Agreements ("MSA") with new pharmaceutical partners in Q3-2024, bringing the business' cumulative total to 27 signed MSAs with life science partners, which include 6 of the top 10 pharmaceutical companies in the world, compared to 12 cumulative signed MSA at the beginning of the year. HEALWELL also generated revenue from 23 pharmaceutical or life sciences customers in Q3-2024, compared to 8 pharmaceutical or life sciences customers that generated patient identification revenue in Q4-2023, demonstrating successful progress in the commercialization of its AI solutions in the healthcare and life science sectors since the beginning of this year.

YTD Comparison of Signed MSAs and Revenue-Generating Pharma or Life Science Partners

	Q4-2023	Q3-2024
Total cumulative # of signed MSAs	12	27
# of Pharma or Life Sciences customers that generated revenue in the quarter	8	23